These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 30502220)

  • 21. Polypill: an affordable strategy for cardiovascular disease prevention in low-medium-income countries.
    López-Jaramillo P; González-Gómez S; Zarate-Bernal D; Serrano A; Atuesta L; Clausen C; Castro-Valencia C; Camacho-Lopez P; Otero J
    Ther Adv Cardiovasc Dis; 2018 Jun; 12(6):169-174. PubMed ID: 29546816
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The polypill: a potential global solution to cardiovascular disease.
    Nguyen C; Cheng-Lai A
    Cardiol Rev; 2013; 21(1):49-54. PubMed ID: 23018668
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The polypill approach - An innovative strategy to improve cardiovascular health in Europe.
    Fuster V; Gambús F; Patriciello A; Hamrin M; Grobbee DE
    BMC Pharmacol Toxicol; 2017 Feb; 18(1):10. PubMed ID: 28166827
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiovascular disease in women: Executive summary of the expert panel statement of women in cardiology of the hellenic cardiological society.
    Chrysohoou C; Aggeli C; Avgeropoulou C; Aroni M; Bonou M; Boutsikou M; Brili S; Chamodraka E; Dagre A; Flevari P; Fountoulaki A; Frogoudaki A; Gkouziouta A; Grapsa J; Hatzinikolaou-Kotsakou E; Kalantzi K; Kitsiou A; Kostakou P; Kourea R; Koutrolou-Sotiropoulou P; Marketou M; Mavrogeni S; Naka KK; Nikolaou M; Papazachou O; Papavasileiou LP; Simeonidou E; Theopistou A; Triantafyllidi H; Trikka C; Tsekoura D; Tzifa A; Vaina S; Vrettou AR; Zaglavara T; Kolovou G;
    Hellenic J Cardiol; 2020; 61(6):362-377. PubMed ID: 33045394
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient preferences for a polypill for the prevention of cardiovascular diseases.
    Laba TL; Howard K; Rose J; Peiris D; Redfern J; Usherwood T; Cass A; Patel A; Jan S
    Ann Pharmacother; 2015 May; 49(5):528-39. PubMed ID: 25680761
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current status of nuclear cardiology practice in Latin America and the Caribbean.
    Paez D; Peix A; Orellana P; Vitola J; Mut F; Gutiérrez C; Plaza C; Becic T; Dondi M; Estrada E;
    J Nucl Cardiol; 2017 Feb; 24(1):308-316. PubMed ID: 27572926
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adherence to therapies for secondary prevention of cardiovascular disease: a focus on aspirin.
    Packard KA; Hilleman DE
    Cardiovasc Ther; 2016 Dec; 34(6):415-422. PubMed ID: 27473898
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polypill and global cardiovascular health strategies.
    Sanz G; Fuster V
    Semin Thorac Cardiovasc Surg; 2011; 23(1):24-9. PubMed ID: 21807295
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimal pharmacological treatment and adherence to medication in secondary prevention of cardiovascular events in Spain: Results from the CAPS study.
    Cordero A; Rodriguez Padial L; Batalla A; López Barreiro L; Torres Calvo F; Castellano JM; Ruiz E; Bertomeu-Martínez V;
    Cardiovasc Ther; 2017 Apr; 35(2):. PubMed ID: 27957818
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Heart of 25 by 25: Achieving the Goal of Reducing Global and Regional Premature Deaths From Cardiovascular Diseases and Stroke: A Modeling Study From the American Heart Association and World Heart Federation.
    Sacco RL; Roth GA; Reddy KS; Arnett DK; Bonita R; Gaziano TA; Heidenreich PA; Huffman MD; Mayosi BM; Mendis S; Murray CJ; Perel P; Piñeiro DJ; Smith SC; Taubert KA; Wood DA; Zhao D; Zoghbi WA
    Glob Heart; 2016 Jun; 11(2):251-64. PubMed ID: 27174522
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Atherogenic Dyslipidemia in Latin America: Prevalence, causes and treatment: Expert's position paper made by The Latin American Academy for the Study of Lipids (ALALIP) Endorsed by the Inter-American Society of Cardiology (IASC), the South American Society of Cardiology (SSC), the Pan-American College of Endothelium (PACE), and the International Atherosclerosis Society (IAS).
    Ponte-Negretti CI; Isea-Perez JE; Lorenzatti AJ; Lopez-Jaramillo P; Wyss-Q FS; Pintó X; Lanas F; Medina J; Machado-H LT; Acevedo M; Varleta P; Bryce A; Carrera C; Peñaherrera CE; Gómez-M JR; Lozada A; Merchan-V A; Piskorz D; Morales E; Paniagua M; Medina-Palomin F; Villar-M RA; Cobos L; Gómez-Alvares E; Alonso R; Colan J; Chirinos J; Lara J; Ullauri V; Arocha I
    Int J Cardiol; 2017 Sep; 243():516-522. PubMed ID: 28552520
    [TBL] [Abstract][Full Text] [Related]  

  • 32. How to optimize the adherence to a guideline-directed medical therapy in the secondary prevention of cardiovascular diseases: a clinical consensus statement from the European Association of Preventive Cardiology.
    Pedretti RFE; Hansen D; Ambrosetti M; Back M; Berger T; Ferreira MC; Cornelissen V; Davos CH; Doehner W; de Pablo Y Zarzosa C; Frederix I; Greco A; Kurpas D; Michal M; Osto E; Pedersen SS; Salvador RE; Simonenko M; Steca P; Thompson DR; Wilhelm M; Abreu A
    Eur J Prev Cardiol; 2023 Jan; 30(2):149-166. PubMed ID: 36098041
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The use of the CNIC-Polypill in real-life clinical practice: opportunities and challenges in patients at very high risk of atherosclerotic cardiovascular disease - expert panel meeting report.
    Grigorian-Shamagian L; Coca A; Morais J; Perez-Martinez P;
    BMC Proc; 2023 Aug; 17(Suppl 8):20. PubMed ID: 37587509
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Future of polypill use for the prevention of cardiovascular disease and strokes.
    Chrysant SG; Chrysant GS
    Am J Cardiol; 2014 Aug; 114(4):641-5. PubMed ID: 24996555
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Strengths and Limitations of Using the Polypill in Cardiovascular Prevention.
    Roy A; Naik N; Srinath Reddy K
    Curr Cardiol Rep; 2017 May; 19(5):45. PubMed ID: 28425033
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polypill Variants (Quarter Pill Trials).
    Teo K; Yusuf S
    Am J Hypertens; 2018 Jun; 31(7):758-761. PubMed ID: 29554202
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lifestyle and risk factor management in people at high risk of cardiovascular disease. A report from the European Society of Cardiology European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV cross-sectional survey in 14 European regions.
    Kotseva K; De Bacquer D; De Backer G; Rydén L; Jennings C; Gyberg V; Abreu A; Aguiar C; Conde AC; Davletov K; Dilic M; Dolzhenko M; Gaita D; Georgiev B; Gotcheva N; Lalic N; Laucevicius A; Lovic D; Mancas S; Miličić D; Oganov R; Pajak A; Pogosova N; Reiner Ž; Vulic D; Wood D; On Behalf Of The Euroaspire Investigators
    Eur J Prev Cardiol; 2016 Dec; 23(18):2007-2018. PubMed ID: 27638542
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Usefulness of a Cardiovascular Polypill in the Treatment of Secondary Prevention Patients in Spain: A Cost-effectiveness Study.
    Barrios V; Kaskens L; Castellano JM; Cosin-Sales J; Ruiz JE; Zsolt I; Fuster V; Gracia A
    Rev Esp Cardiol (Engl Ed); 2017 Jan; 70(1):42-49. PubMed ID: 27474481
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of the cardiovascular polypill 40mg in secondary cardiovascular prevention.
    Marzal D; Rodríguez Padial L; Arnáiz JA; Castro A; Cosín J; Lekuona I; Guijarro C
    Clin Investig Arterioscler; 2018; 30(5):240-247. PubMed ID: 30017176
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Position statement of the Interamerican Society of Cardiology (IASC) on the current guidelines for the prevention, diagnosis and treatment of arterial hypertension 2017-2020.
    Wyss F; Coca A; Lopez-Jaramillo P; Ponte-Negretti C; ;
    Int J Cardiol Hypertens; 2020 Sep; 6():100041. PubMed ID: 33447767
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.